Defining the role of neoadjuvant systemic therapy in high‐risk retroperitoneal sarcoma: A multi‐institutional study from the Transatlantic Australasian Retroperitoneal Sarcoma Working Group
William W. Tseng(Brigham and Women's Hospital), Alessandro Gronchi(Fondazione IRCCS Istituto Nazionale dei Tumori), Samuel Ford(University Hospitals Birmingham NHS Foundation Trust), Hannah L. Tattersall(NIHR Surgical Reconstruction and Microbiology Research Centre), Kenneth Cardona(Emory University), Ty K. Subhawong(University of Miami), James Hu(University of Southern California), Valerie P. Grignol(Ohio State University Hospital), Antonino De Paoli(Centro di Riferimento Oncologico), Giovanni Grignani(Candiolo Cancer Institute), Francesco Barretta(Fondazione IRCCS Istituto Nazionale dei Tumori), Francesco Tolomeo(Candiolo Cancer Institute), Chandrajit P. Raut(Dana-Farber Cancer Institute), Carolyn Nessim(University of Ottawa), Roberta Sanfilippo(Fondazione IRCCS Istituto Nazionale dei Tumori), Federico Navarria(Centro di Riferimento Oncologico), Markus Albertsmeier(LMU Klinikum), Piotr Rutkowski(The Maria Sklodowska-Curie National Research Institute of Oncology), Mark Fairweather(Brigham and Women's Hospital), Jeffrey M. Farma(Fox Chase Cancer Center), Margaret von Mehren(Temple University Health System), Lorenzo Conti(Fondazione IRCCS Istituto Nazionale dei Tumori), Rachel Lee(Texas Department of State Health Services), Martin K. Angele(Ludwig-Maximilians-Universität München), Jacek Skoczylas(The Maria Sklodowska-Curie National Research Institute of Oncology), Neha Goel(University of Miami)
Cited by 48
Related Papers
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
|New England Journal of Medicine|2014|2.7k
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
|New England Journal of Medicine|2017|2.2k
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
|New England Journal of Medicine|2018|1.9k